Table 1.

Highlight on some recent studies exploring the efficacy of different direct acting antivirals combinations in Egypt

Ref.	Year of publication	Number of patients	Regimen used	Sustainted virologic response rate
Ruane et al[22]	2015	60	Sofosbuvir and ribavirin for 12 wk or 24 wk	68% for 12 wk or 24 wk and 93% for patients treated for 24 wk
Doss et al[23]	2015	103	Sofosbuvir and ribavirin for 12 wk or 24 wk	77% in patients treated for 12 wk and 90% for patients treated for 24 wk
Elsharkawy et al[24]	2017	14409	Triple; sofosbuvir, pegylated interferon and ribavirin versus dual; sofosbuvir and ribavirin	94% with triple therapy and 78.7% with dual therapy
El Kassas et al[25]	2018	7042	Different combinations used	82.9%-100.0%
Ahmed et al[26]	2018	300	Sofosbuvir plus daclatasvir with or without ribavirin for 12-24 wk	96.55% and 84.54%
Abd-Elsalam et al[27]	2018	2400	Sofosbuvir and ribavirin	71.20%.
El Kassas et al[28]	2018	10083	A 4-wk lead-in phase of sofosbuvir, pegylated interferon and ribavirin followed by 12 wk therapy with sofosbuvir and daclatasvir versus 12 wk therapy with sofosbuvir and daclatasvir	100% in those whoe received the lead in phase treatment regimen and 98.9% in those who received sofosbuvir and daclatasvir only
El-Khayat et al[29]	2017	583	Sofosbuvir and simeprevir for 12 wk	95.70%
Eletreby et al[30]	2017	6211	Sofosbuvir and simeprevir for 12 wk	94.00%
Abdel-Moneim et al[31]	2018	946	Sofosbuvir, daclatasvir versus Sofosbuvir, daclatasvir and ribavirin	95% and 92%
Omar et al[34]	2018	18378	Daclatasvir plus sofosbuvir	95.10%.
El-Khayat et al[35]	2018	144	Ledipasvir plus sofosbuvir	99.00%
Elsharkawy et al[36]	2018	337042	Different combinations used	82.7% to 98.0%